Galderma S.A. will launch its first-ever therapeutic biologic in 2024, assuming US Food and Drug Administration approval is granted later this year, and presented long-term data at the American Academy of Dermatology (AAD) meeting in San Diego that it believes will make the case for preferential use of its IL-31 receptor alpha inhibitor nemolizumab in prurigo nodularis (PN) and in certain Dupixent (dupilumab)-treated and -naïve patients with atopic dermatitis (AD).
Key Takeaways
-
Galderma reported positive longer-term data for its IL-31 inhibitor nemolizumab in prurigo nodularis (PN) and atopic dermatitis (AD) that it believes differentiate the drug, including versus market leader Dupixent (dupilumab).
The private Swiss company, which announced on 6 March that it plans to go public on the SIX Swiss Exchange,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?